sotorasib
sotorasib: 19 clinical trials tracked.
sotorasib evidence translation
What we can confirm
19 tracked trials
What it means
What to watch
Prepared research question
What is verified about sotorasib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 6 study sponsors
Related indications
Clinical Trials (19)showing 10 most recent
A Multicenter, Open-label, Single-arm, Expanded Access Protocol of Sotorasib for the Treatment of Subjects With Previously Treated Locally Advanced Unresectable/Metastatic NSCLC With KRAS p.G12C Mutation
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
Primary endpoint: safety and adverse events (AEs)
A Rollover Study of Sotorasib With or Without Panitumumab for the Treatment of Cancer Subjects With KRAS p.G12C Mutation Previously Treated in an Amgen-Sponsored Study
Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients
Primary endpoint: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
BrainMet ADePPT (Anticancer Drug Penetration Platform Trial)
Primary endpoint: ORR (overall response rate)
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)
Primary endpoint: Number of Participants Experiencing Dose Limiting Toxicities (DLT)
A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial
Primary endpoint: Progression-free survival (PFS) (Cohort I)
Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
Primary endpoint: PFS per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)
Primary endpoint: Progression-free Survival (PFS)
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Primary endpoint: Accrual of patients to ComboMATCH treatment trials